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Th17 cytokinea b s t r a c t
We reported previously that a synthetic mucosal adjuvant SF-10, which mimics human pulmonary sur-
factant, delivers antigen to mucosal dendritic cells in the nasal cavity and promotes induction of humoral
and cellular immunity. The aim of the present study was to determine the effects of oral administration of
antigen combined with SF-10 (antigen-SF-10) on systemic and local immunity. Oral administration of
ovalbumin, a model antigen, combined with SF-10 enhanced ovalbumin uptake into intestinal antigen
presenting MHC II+CD11c+ cells and their CD11b+CD103+ and CD11b+CD103- subtype dendritic cells,
which are the major antigen presenting subsets of the intestinal tract, more efficiently compared to with-
out SF-10. Oral vaccination with influenza hemagglutinin vaccine (HAv)-SF-10 induced HAv-specific IgA
and IgG in the serum, and HAv-specific secretory IgA and IgG in bronchoalveolar lavage fluid, nasal
washes, gastric extracts and fecal material; their levels were significantly higher than those induced
by subcutaneous HAv or intranasal HAv and HAv-SF-10 vaccinations. Enzyme-linked immunospot assay
showed high numbers of HAv-specific IgA and IgG antibody secreting cells in the gastrointestinal and res-
piratory mucosal lymphoid tissues after oral vaccination with HAv-SF-10, but no or very low induction
following oral vaccination with HAv alone. Oral vaccination with HAv-SF-10 provided protective immu-
nity against severe influenza A virus infection, which was significantly higher than that induced by HAv
combined with cholera toxin. Oral vaccination with HAv-SF-10 was associated with unique cytokine pro-
duction patterns in the spleen after HAv stimulation; including marked induction of HAv-responsive
Th17 cytokines (e.g., IL-17A and IL-22), high induction of Th1 cytokines (e.g., IL-2 and IFN-c) and moder-
ate induction of Th2 cytokines (e.g., IL-4 and IL-5). These results indicate that oral vaccination with HAv-
SF-10 induces more efficient systemic and local immunity than nasal or subcutaneous vaccination with
characteristically high levels of secretory HAv-specific IgA in various mucosal organs and protective
immunity.
 2018 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Influenza virus infects approximately 10–20% of the world pop-
ulation annually, causing death of approximately 290,000 to
650,000 individuals [1]. Since several types of influenza virus
spread globally among humans as well as pets and other domestic
animals [2–5], there is a need for effective influenza vaccines for
both human and animals. In particular, induction of protective
immunity in the respiratory and gastrointestinal mucosae is
important for protection against influenza virus infection, becauseseasonal influenza viruses grow in the respiratory mucosa and the
highly pathogenic avian influenza viruses grow in both the respira-
tory and gut mucosae [6–8].
The currently available influenza vaccines administered intra-
muscularly or subcutaneously induce a predominant IgG-
mediated protection in the systemic immune compartment [9],
but hardly induce adequate production of antiviral secretory IgA
(S-IgA) for protection against infection in the airway mucosa, the
site of viral entry and propagation. To overcome this shortfall, pre-
vious studies investigated the benefits of intranasal mucosal vac-
cine adjuvant, which can induce both S-IgA in the airway mucosa
and IgG in serum [9–12]. However, many such vaccines were found
ineffective or had safety problems [11,13]. We reported previously
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intranasal mucosal adjuvant for influenza ether split hemagglu-
tinin vaccine (HAv) and showed potent enhancement of humoral
immune responses without adverse reactions in the mouse and
swine [11,14]. Pulmonary surfactant shows potent adjuvanticities
as a delivery vehicle by promoting antigens uptake into mucosal
antigen presenting cells (APCs), such as dendritic cells (DCs), but
itself does not stimulate APCs without antigen [11,15]. Among
the various constituents of human pulmonary surfactant, we found
three major lipids; 1,2-dipalmitoyl-phosphatidylcholine (DPPC),
phosphatidylglycerol (PG), and palmitic acid (PA), together with
surfactant protein C (SP-C), to be essential constituents for its
mucosal adjuvanticity [15]. We also prepared a synthetic surfac-
tant (SSF) of these constituents that mimics the antigen delivery
activity of pulmonary surfactant. Furthermore, we recently
improved the SSF for large-scale manufacturing and enhancement
of its adjuvanticity [12].
Since the hydrophobic peptide SP-C does not dissolve in com-
mon organic solvents, we selected K6L16 peptide among the SP-
C related peptides, as a substitute for human SP-C, which is soluble
in methanol and ethanol and expresses high adjuvanticity [12]. To
achieve more efficient antigen delivery activity for SSF, we added
carboxy vinyl polymer (CVP) to increase the viscosity of antigen-
SSF complex and prolong antigen uptake time on the mucosal sur-
face. Based on these improvements, the manufactured pulmonary
surfactant mimicked the synthetic adjuvant, which is useful for
ample supply and shows enhanced adjuvanticity, and termed the
improved adjuvant compound SF-10 [12]. Antigen combined with
SF-10 (antigen-SF-10) enhances absorption of antigens into nasal
APCs and induces systemic and respiratory humoral immunity
with induction of balanced antigen specific Th1/Th2 cells in mice
and cynomolgus monkeys [12,16] and systemic cell-mediated
immunity as well in mice [17].
The pulmonary surfactant is a biologically active natural sub-
stance secreted by alveolar type II epithelial cells, rapidly metabo-
lized in the lungs, coats the alveolar surface, and lowers the surface
tension of the air-liquid interface to prevent alveolar collapse [18].
Previous studies indicated a progressive increase in micelles of pul-
monary surfactant in human amniotic fluid at term and that the
micelles in the amniotic fluid are swallowed by the fetus [19,20].
More recently, Nishijima et al. [21] reported that the micelles swal-
lowed by the fetus are absorbed by the intestinal mucosal epithe-
lium where they stimulate villous height maturation. These
findings suggest that pulmonary surfactant has a physiological
function in the gastrointestinal tract apart from its function in
the respiratory tract through efficient absorption by the intestinal
mucosal epithelium. Accordingly, it is assumed that effective anti-
gen presentation in the gastrointestinal mucosal APCs can be
achieved by oral vaccination of antigen-SF-10 complex through
the delivery activity of pulmonary surfactant to the gastrointesti-
nal mucosal epithelium.
Although oral vaccination could result in gastrointestinal anti-
gen digestion and acid inactivation of the antigen, compared with
nasal vaccination, various oral influenza vaccines, combined with
adjuvants, such as heat-labile enterotoxin-based adjuvants
[22,23], liposome-based adjuvant [24], and influenza DNA vaccines
using adenovirus vector [25,26], plasmid vector [27], and Sal-
monella vector [28,29] have been used. Although these oral influ-
enza vaccines require higher doses of antigen by several orders
of magnitude [30], the level of induced immunity was relatively
lower than that achieved through nasal and subcutaneous vaccina-
tions. In this regard, whereas oral administration of DNA vaccines
can reduce vaccine doses, it carries the risk of releasing genetically
modified organisms to nature.
The aim of the present study was to determine the effects of
oral administration of HAv-SF-10 into the gastrointestinal tract ofmice on respiratory, gastrointestinal and systemic immunity. For
this purpose, we analyzed the induction of HAv-specific antibody
secreting cells (ASCs) in the respiratory and gut organ-associated
lymphoid tissues, and the levels of cytokines secreted by HAv
responsive helper T cells in the spleen of immunized mice to eval-
uate the Th1/Th2/Th17 immunity balance. We also assessed the
level of protective immunity induced by oral administration of
HAv-SF-10 against severe influenza A virus (IAV) challenge in a
mouse model of acute pneumonia.2. Materials and methods
2.1. Vaccine, virus and animals
Split product of HAv of IAV/California/7/2009(H1N1) was pur-
chased from Kitasato Daiichi Sankyo Vaccine Co. (Tokyo, Japan).
IAV/ PR8/34(H1N1) was provided by The Research Foundation for
Microbial Diseases of Osaka University (Kagawa, Japan). Female
BALB/c mice (age 6–8 weeks) were purchased from Japan SLC (Shi-
zuoka, Japan). All animals were maintained under specific-
pathogen-free conditions. Mice were anesthetized by intraperi-
toneal injection of 62.6 mg ketamine and 12.4 mg xylazine per kg
body weight before vaccine administration and infection. All mice
used in this study were treated according to the Guide for the Care
and Use of Laboratory Animals (NIH Publication No. 85–23, 1996).
The study was approved by the Animal Care Committee of Tokush-
ima University (#T27-109).
2.2. Preparation of antigen-SF-10
The procedure for preparation of SSF was reported in detail pre-
viously [15]. Briefly, SSF was prepared by mixing three major lipids
of pulmonary surfactant, DPPC, PG and PA, and a cationic
hydrophobic peptide K6L16, which mimics SP-C, at a weight ratio
of 75:25:10:2. SSF was mixed with HAv or Alexa647-labeled oval-
bumin (fOVA, Thermo Fisher Scientific, Middletown, VA) at a SSF
phospholipid:antigen protein ratio of 10:1 at 42 C, and the stable
antigen-SSF complex was prepared by lyophilization and stored at
20 C until use. To prepare 1% CVP (HIVISWAKO104, FUJIFILM
Wako Pure Chem. Co., Osaka, Japan) solution, CVP powder was dis-
solved in saline by stirring followed by sonication and then stored
at 4 C until use. Before administration, lyophilized antigen-SSF
was dissolved with 1% CVP by mild mixing and then equal volume
of saline [12] or 50 mM sodium bicarbonate buffer, pH 9.7, (carbo-
buffer) was added. The final solution in the presence of CVP was
termed antigen-SF-10.
2.3. Immunization and sampling of serum and mucosal fluid
After starvation for 4 h, one group of mice were orally adminis-
tered 1 lg HAv with or without 10 lg phospholipid-containing SF-
10 [HAv-SF-10(p.o.)], lipopolysaccharide (LPS) (Nacalai tesque,
Kyoto, Japan), Pam3CSK4 (InvivoGen, San Diego, CA), poly(I:C)
(Alexis Biochemicals, Lausanne, Switzerland), CpG (InvivoGen),
cholera toxin B subunit (CT-B) (Sigma-Aldrich, St. Louis, MO), or
cholera toxin (CT) (Millipore, Billerica, MA) in 200 lL of 25 mM
carbo-buffer by using a stainless steel mouse feeding needle
(Fuchigami Co., Ltd., Kyoto, Japan, No. 4202, L  diam.
38  0.62 mm), connected to a 1 mL plastic syringe, four times vac-
cination at days 0, 3, 14, and 17 or at the indicated time points of
vaccination schedule described in the legends for figures. Another
group of mice was inoculated intranasally with 1 lg HAv with or
without 10 lg SF-10 in 6 lL of saline (3 lL/each nostril) [HAv-SF-
10(i.n.)] by using a Eppendorf Research plus pipette, Z683787
Aldrich or subcutaneously injected with 1 lg HAv in 100 lL saline
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respectively. After 2 weeks from the last inoculation, serum, nasal
washes, and bronchoalveolar lavage fluids (BALF) were prepared as
described previously [11]. The gastric extract was prepared by
allowing the stomach to stand in a 2% saponin (Nacalai tesque)-
PBS overnight at 4 C. Fecal extract was prepared by extraction of
100 mg feces from the cecum with 500 lL phosphate-buffered sal-
ine (PBS) containing protease inhibitors, e.g., 0.32 mg/mL benza-
mide (Sigma-Aldrich) and 2 lg/mL phenylmethylsulfonyl fluoride
(Nacalai tesque).
2.4. Measurement of antigen uptake by small intestinal mucosal cells
Mice were orally administrated of 100 lg fOVA with or without
SF-10. At 12 or 24 h after vaccination, small intestinal mucosal cells
were isolated, and the epithelial layer cells and lamina propria
layer cells were purified separately by 2 mM EDTA (Nacalai tesque)
solution and 1.5 mg/mL collagenase type IV (Gibco, Grand Island,
NY) in Ca2+- and Mg2+-free Hank’s balanced salt solution, respec-
tively, as described in detail previously [31]. These cells were
stained with anti-mouse I-A/I-E (MHC II), CD11b, CD11c and
CD103 (BioLegend, San Diego, CA) and analyzed by FACSVerse
(BD Biosciences, Franklin Lakes, NJ) and Flowjo software (Tree Star
Inc., Ashland, OR).
2.5. Measurement of HAv-specific IgA, S-IgA and IgG
Two weeks after the last immunization, we measured HAv-
specific IgA and IgG levels in the serum and HAv-specific S-IgA
and IgG levels in the mucosal fluid by enzyme-linked immunosor-
bent assay (ELISA), as described previously [15]. We used goat anti-
mouse IgA and anti-mouse IgG antibody conjugated with horse-
radish peroxidase (Sigma-Aldrich) as the secondary antibodies.
HAv-specific IgA, S-IgA and IgG levels were calculated by using
affinity-purified mouse HAv-specific IgA and IgG as standards, as
described previously [11].
2.6. Detection of HAv-specific antibody secreting cells in lymph nodes
by ELISPOT assay and measurement of HAv responsive cytokine levels
in the spleen
Two weeks after the fourth oral vaccination, the spleen, cervical
lymph nodes (CLN), mesenteric lymph nodes (MLN), Peyer’s
patches (PP), gastric lymph nodes (GLN), and lung lymph nodes
were isolated from mice immunized with HAv or HAv-SF-10 in
carbo-buffer. The lymphocytes from the spleen, CLN, PP, MLN,
and GLN were purified according to the method described previ-
ously [17] while those from lung were purified by collagenase
digestion followed by Percoll (GE Healthcare, Buckinghamshire,
UK) density gradient centrifugation, as described previously [17].
For detection of HAv-specific ASCs by enzyme-linked immuno-
spot (ELISPOT) assay, the isolated lymphocytes from each organ,
except the lung, were incubated for 3 days with 1 lg/mL R848
(Novus Biologicals, Littleton, CO) and 10 ng/mL rmIL-2 (BioLegend)
in complete RPMI (cRPMI) medium (containing 10 mM HEPES, pH
7.2, 1 mM sodium pyruvate, 1% MEM non-essential amino acids
solution, 14.3 lM 2-mercaptoethanol, 10 lg/mL gentamycin and
10% heat-inactivated fetal bovine serum). The incubated lympho-
cytes and non-incubated lung lymphocytes isolated from mice
immunized orally with HAv or HAv-SF-10 were counted by
LUNA-IITM Automated Cell Counter (Logos Biosystems, Anyang,
Korea). The lymphocytes were then seeded at the indicated num-
ber (from 105 to 106 cells/well) onto MultiScreen 96-well plates
MSIPS4510 (Millipore), which were pre-coated with 1 lg HAv pro-
tein/well, and incubated with fresh cRPMI for 4 h (lung lympho-
cytes) or 24 h (excluding lung lymphocytes). After incubation, thespots of HAv-specific ASCs were detected by goat anti-mouse IgA
or anti-mouse IgG antibody conjugated with horseradish peroxi-
dase (Sigma-Aldrich) and 3-amino-9-ethylcarbazole (Sigma-
Aldrich). The number of ASC spots was counted by ELISPOT counter
ImmunoSpot S6 (CTL, Cleveland, OH).
For measurement of cytokine levels secreted by HAv-responsive
splenocytes of mice immunized subcutaneously, intranasally or
orally with HAv or HAv-SF-10, isolated splenocytes were incubated
with cRPMI medium with or without 10 lg HAv per 106 cells/mL
for 3 days. The concentration of IL-2, IL-4, IL-5, IL-17A, IL-21 and
IFN-c in the culture media supernatant was measured by
LEGENDplexTM and analyzed by LEGENDplexTM Data Analysis Soft-
ware (BioLegend) according to the protocols provided by the
manufacturers.
2.7. Hemagglutination inhibition assay
Hemagglutination inhibition (HI) activity was measured as
described previously [14]. Serum was treated overnight with RDE
(II) ‘‘SEIKEN” (Denka Seiken Co., Tokyo, Japan) at 37 C. The treated
serum was diluted in 96-well plates, and then 4 HA units of the
vaccine antigen and 0.75% of washed chicken red blood cells were
added to each well, and incubated for 30 min at room temperature.
The HI endpoint titers represented the reciprocal of the highest
serum dilution that produced complete inhibition of hemaggluti-
nating activity.
2.8. Protection against virus challenge in mice after oral vaccination
To assess the efficacy of protective immunity after oral vaccina-
tion, BALB/c mice were immunized twice orally with HAv, HAv-SF-
10 or carbo-buffer at days 0 and 3, and then all mice were infected
intranasally with 20 lL of IAV/ PR8/34(H1N1) at a dose of
50  LD50 (50 PFU) at 14 days after the last immunization. At days
4 and 7 after infection, the virus titers in BALF were measured by
the plaque assay using Madin-Darby canine kidney cells and
anti-IAV nucleoprotein monoclonal antibody, as described previ-
ously [32].
Another group of BALB/c mice was immunized twice orally
with HAv, HAv-SF-10 or HAv-CT at days 0 and 3, and then all
mice were infected intranasally with 20 lL of a lethal dose of
IAV/ PR8/34(H1N1) (50 to 1000 PFU), and the survival and body
weight loss were monitored during the period of 15 days after
infection.
2.9. Statistical analysis
Data were expressed as mean ± SEM. Statistical significance of
the differences between experimental groups was calculated by
ANOVA with a Bonferroni posttest, an unpaired Student’s t-test
(if variances were equal (F-test, P  0.05)) or Welch’s t-test (if vari-
ances were unequal (F-test, P < 0.05)) using KaleidaGraph 4.5 soft-
ware (Synergy Software, Reading, PA). Survival rate was analyzed
by the Kaplan-Meier and log-rank tests. P values less than 0.05
were considered statistically significant.3. Results
3.1. SF-10 increases antigen uptake into intestinal APCs
To assess the effects of SF-10 on antigen uptake into intestinal
APCs, mice were orally administrated reporter antigen fOVA and
fOVA-SF-10 for 12 h and 24 h, and APCs in the epithelial and lamina
propria layers of the small intestine were isolated. fOVA-labelled
MHC II+CD11c+ cells (APCs), and CD11b+CD103+ and CD11b+CD103-
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detected by flow cytometry (Fig. 1A-E). The percentages of fOVA-
labelled cells among the APCs (Fig. 1F), CD11b+CD103+ DCs
(Fig. 1G) and CD11b+CD103- DCs (Fig. 1H) in the epithelial and lam-
ina propria layers indicated that SF-10 significantly increased fOVA-
uptake into the intestinal APCs after administration for 12 h, com-
pared with those induced by fOVA alone. However, the percentages
of fOVA-labelled cells in APCs were markedly decreased after
administration for 24 h and no significant differences were
detected between fOVA and fOVA-SF-10 treatedmice. These results
indicate that SF-10 adjuvant enhances antigen uptake into APCs in
the gastrointestinal mucosa for at least 12 h.Fig. 1. SF-10 enhances antigen uptake by intestinal mucosal APCs. BALB/c mice was admi
the mucosal epithelial layer cells (B, D) and lamina propria layer cells (C, E) of the small i
APCs, and CD11b+CD103+ and CD11b+CD103- DCs, was analyzed by flow cytometry. (A)
from non-treated mice (gray), fOVA- (dashed line) and fOVA-SF-10- (solid line) immuni
CD11b+CD103+ DCs (G), and CD11b+CD103- DCs (H). Data are mean ± SEM and were ana
test (n = 5). *P < 0.05. Experiments were independently repeated two times with 5 mice3.2. Oral vaccination of HAv-SF-10 induces higher levels of HAv-
specific IgA and IgG levels in serum and HAv-specific S-IgA and IgG in
various mucosal fluids compared with nasal and subcutaneous
vaccination and increases HAv-specific IgA and IgG ASCs in various
lymph nodes throughout the body
To compare the effects of oral vaccination of HAv-SF-10 on the
induction of humoral immune responses with other administration
routes of vaccination, mice were immunized orally, intranasally
and subcutaneously 4 times with the same administration doses
of HAv and HAv-SF-10. The serum, BALF, nasal washes, and gastric
and fecal extracts were prepared at 2 weeks after the last immu-nistrated fOVA or fOVA-SF-10 orally. At 12 h (B, C) or 24 h (D, E) after administration,
ntestine were isolated. fOVA uptake into the intestinal cells, such as MHC II+CD11c+
The gating strategy of each cell population. (B-E) fOVA uptake into each type of cell
zed mice. (F-H) Percentages of fOVA incorporated cells in MHC II+CD11c+ APCs (F),
lyzed for statistical significance by using independent Student’s t-test or Welch’s t-
per group.
Fig. 2. Comparison of the effects of immunization with HAv-SF-10(p.o,), HAv-SF-10(i.n.), HAv(p.o.), HAv(i.n.) or HAv(s.c.) on mucosal and systemic immunity. Mice were
immunized four times by intranasal (i.n.) or oral administration (p.o.) of HAv combined with or without SF-10 at days 0, 3, 14, and 17. Another group of mice were immunized
with HAv subcutaneously (s.c.) at the same time schedules. At 2 weeks after the last immunization, the levels of HAv-specific IgA and IgG antibodies in serum (A) and HAv-
specific S-IgA and IgG antibodies in BALF (B), nasal washes (C), gastric extract (D) and fecal extracts (E) were measured by ELISA. Data are mean ± SEM of IgA or S-IgA (open
column) and IgG (closed column) of 6 mice and statistical significance was analyzed by using ANOVA with a Bonferroni posttest. *P < 0.05, **P < 0.01. Experiments were
independently repeated two times with 6 mice per group.
616 T. Kimoto et al. / Vaccine 37 (2019) 612–622nization, and the HAv-specific IgA, S-IgA and IgG antibodies of
these specimens were measured by ELISA (Fig. 2). Administration
of HAv alone without SF-10, either intranasally [HAv(i.n.)] or orally
[HAv(p.o.)], was associated with very low levels of HAv-specificIgA, S-IgA and IgG in all specimens. HAv(s.c.) induced only moder-
ate levels of HAv-specific IgG but not S-IgA and IgA in all speci-
mens. HAv-SF-10(i.n.) was associated with significantly higher
levels of HAv-specific IgA, S-IgA and IgG in all specimens compared
T. Kimoto et al. / Vaccine 37 (2019) 612–622 617with the levels of HAv(i.n.). In contrast, HAv-SF-10(p.o.) was asso-
ciated with noticeable induction levels of both IgA and IgG in
serum at about 20-fold higher than those by HAv-SF-10(i.n.)
(Fig. 2A) and S-IgA and IgG in BALF at about 700- and 200-fold
higher than those by HAv-SF-10(i.n.), respectively (Fig. 2B). Induc-
tion of HAv-specific IgG by HAv-SF-10(p.o.) was also significantly
higher at about 7-fold that by HAv(s.c.) (Fig. 2A). The induced
levels of HAv-specific S-IgA and IgG in nasal washes (Fig. 2C), gas-Table 1
Serum HI titer after 4 times vaccination.
HI titer
Non treatment <10
HAv (subcutaneously) 1493 ± 213
HAv (intranasally) 30 ± 7
HAv-SF-10 (intranasally) 137 ± 59
HAv (orally) 6 ± 3
HAv-SF-10 (orally) 3307 ± 849
mean ± SEM (n = 6)
Fig. 3. Detection of HAv-specific ASCs in respiratory and gastrointestinal mucosal tissues
and 17. At 2 weeks after the last immunization, lymphocytes from the lungs (A), splee
patches (PP) (E) and gastric lymph nodes (GLN) (F) were isolated. They were then seeded
detected by ELISPOT. Data represent HAv specific S-IgA (circles), IgG (squares) and numbe
not detected. Experiments were independently repeated two times with 5–10 mice pe
**P < 0.01.tric extracts (Fig. 2D) and fecal extracts (Fig. 2E) of mice immu-
nized with HAv-SF-10(p.o.) were significantly higher at about 2-
to 20-fold and 10- to 50- fold, respectively, than those by HAv-
SF-10(i.n.).
The mean HI titers in serum of mice after vaccination 4 times
with HAv-SF-10(p.o.) were the highest at 3307 ± 849 among the
vaccination groups tested (Table 1): 2.2-fold of HAv(s.c.), 24-fold
of HAv-SF-10(i.n.), and those in mice treated with HAv(p.o.) and
HAv(i.n.) were < 40.
To confirm the production sites of HAv-specific IgA, S-IgA and
IgG in mice vaccinated orally 4 times with HAv or HAv-SF-10, we
isolated lymphocytes from the lung, spleen, CLN, MLN, PP and
GLN at 2 weeks after the last immunization, and measured the
HAv-specific IgA and IgG ASCs by ELISPOT assay. Both HAv-
specific IgA and IgG ASCs were detected in all lymphocytes of lung,
spleen, CLN, MLN, PP and GLN of mice immunized with HAv-SF-10
(p.o.), but not those immunized with HAv(p.o.) alone, except detec-
tion of few IgG spots in CLN and spleen (Fig. 3). The numbers of
induced HAv-specific IgA and IgG spots of ASCs in the lung of mice. Mice were immunized four times with HAv-SF-10(p.o.) or HAv(p.o.) at days 0, 3, 14,
n (B), cervical lymph nodes (CLN) (C), mesenteric lymph nodes (MLN) (D), Peyer’s
onto HAv-coated plates at the indicated number of cells, and HAv-specific ASCs were
rs of ASC per 106 cells of individuals (open) and their means (solid) (n = 5–10). N.D.:
r group and statistical significance was analyzed by using Welch’s t-test. *P < 0.05,
618 T. Kimoto et al. / Vaccine 37 (2019) 612–622immunized with HAv-SF-10(p.o.) were the highest among those of
ASCs in the lymph nodes throughout the body analyzed.
3.3. Induction of HAv-specific Th1, Th2 and Th17-type immune
responses following oral vaccination with HAv-SF-10
To analyze the immunological background of high induction
levels of HAv-specific IgG and IgA in serum and HAv-specific S-
IgA in mucosal fluid of mice vaccinated with HAv-SF-10(p.o.), we
measured cytokine induction of HAv-specific Th1, Th2 and Th17-
type immune responses of splenocytes. Mice were immunized four
times with HAv(i.n.), HAv(p.o.), HAv(s.c.), HAv-SF-10(i.n.) and HAv-
SF-10(p.o.), and the splenocytes of these mice were isolated at
2 weeks after the last immunization, followed by incubation with
or without HAv for 3 days. The HAv responsive Th1 (IL-2 and
IFN-c), Th2 (IL-4 and IL-5) and Th17 (IL-17A and IL-22) cytokine
levels in culture media were measured (Table 2). In the absence
of HAv in the culture medium, no significant induction of cytokines
was detected compared with those of no-treatment control in all
the vaccination groups. HAv stimulated the induction of all cytoki-
nes in each group of immunized mice. HAv(s.c.) vaccination
induced both Th1 and Th2 cytokines, and the levels of IL-4 and
IL-5 were the highest among the immunized groups. In contrast,
HAv-SF-10(p.o.) and HAv-SF-10(i.n.) vaccinations mainly increased
the levels of IFN-c, IL-2, IL-17A and IL-22, compared with HAv(p.o.)
and HAv(i.n.), respectively, and the production levels were higher
by HAv-SF-10(p.o.) than by HAv-SF-10(i.n.). These results indicate
that HAv-SF-10(p.o.) vaccination markedly increases Th1 and Th17
cytokine production with moderate Th2 cytokine induction,
whereas Th17 cytokine induction by HAv-SF-10(p.o.), in particular,
is the highest among the immunized groups tested.
3.4. Oral vaccination time schedule and comparison of induction
efficacy of HAv-specific IgG in serum and S-IgA in BALF among various
mucosal adjuvants
To optimize the time of oral vaccination, HAv-SF-10(p.o.) was
administered one to four times, as illustrated in Fig. 4A. The levels
of HAv-specific IgG in serum and HAv-specific S-IgA in BALF were
measured at 2 weeks after the last immunization. Serum IgG and
BALF S-IgA increased exponentially with time of vaccination and
serum HAv-specific IgG levels reached about 500 lg/mL after two
times immunization, the levels were almost equivalent to the IgG
titers with complete protection against severe IAV infection, which
was induced in mice administrated with HAv-SF-10(i.n.), as
reported previously [12]. These data suggest that two-time vacci-
nation with HAv-SF-10(p.o.) can provide protective immunity.
We next compared the induction efficacy of SF-10 and other
mucosal adjuvants on HAv-specific IgG in serum and S-IgA in BALF.
Mice were immunized twice orally with HAv or HAv-SF-10, -LPS, -
Pam3CSK4, -poly(I:C), -CpG, -CT-B, or –CT. Two weeks after the lastTable 2
Cytokine concentrations (pg/mL) in the culture media of splenocytes stimulated with (+)
Th1
IL-2 IFN-c IL
HAv stimulation  +  + 
Non treatment 82 ± 34 40 ± 2 10 ± 5 23 ± 6 1 ± 1 0
HAv (subcutaneously) 59 ± 19 1608 ± 117* 28 ± 14.1 2538 ± 607* 1 ± 1 1
HAv (intranasally) 69 ± 26 547 ± 183** 13 ± 6 575 ± 262** 0 ± 0 5
HAv-SF-10 (intranasally) 75 ± 8 2445 ± 584 8 ± 4 648 ± 298** 0 ± 0 6
HAv (orally) 57 ± 9 61 ± 22*8 6 ± 3 16 ± 7** 0 ± 0 1
HAv-SF-10 (orally) 326 ± 22 3223 ± 611 172 ± 145 5207 ± 639 5 ± 2 1
Data are mean ± SEM and statistical significance was analyzed by using ANOVA with a Boimmunization, the levels of HAv-specific IgG in serum and S-IgA in
BALF were measured by ELISA (Fig. 4C). No significant induction of
HAv-specific IgG in serum and S-IgA in BALF was noted in mice
immunized orally with HAv-LPS, -Pam3CSK4, -poly(I:C), -CpG,
and -CT-B, compared with immunization using HAv alone. Among
the tested adjuvants derived from bacteria and virus origins, only
CT with HAv [HAv-CT(p.o.)] was associated with induction of
HAv-specific IgG in serum and very low levels of HAv-specific S-
IgA in BALF, but the levels were significantly lower than those of
mice immunized with HAv-SF-10(p.o.). The induced levels of
HAv-specific IgG by HAv-SF-10(p.o.) were 5.5-fold higher in serum
and HAv-specific S-IgA were 63-fold higher in BALF, compared
with those induced by HAv-CT(p.o.).
3.5. Protective immunity induced by oral vaccination of HAv-SF-10
Finally, we analyzed the protective immunity induced by two-
time vaccination with HAv-SF-10(p.o.), by comparing HI titers in
serum with those of HAv(p.o.) and HAv-CT(p.o.) (Fig. 5A). The
induced HI titer of HAv-SF-10(p.o.) was > 160, which was signifi-
cantly higher than that of HAv-CT(p.o.).
Fig. 5B shows the neutralization activities of BALF in mice
immunized with HAv-SF-10(p.o.), HAv(p.o.) and carbo-buffer (neg-
ative control). Immunized mice were infected with IAV/PR8(H1N1)
at a lethal dose of 50 PFU (50  LD50) at 2 weeks after the last
immunization and then virus titers in BALF were measured at days
4 and 7 after infection. More than 104 PFU/mL of IAV was detected
in BALF of mice immunized with carbo-buffer and HAv(p.o.) at
days 4 and 7, but only 20 PFU/mL at day 4 and below the detection
levels at day 7 were detected in the BALF of mice immunized with
HAv-SF-10(p.o.).
We also monitored the survival rates (Fig. 5C) and changes in
body weight (Fig. 5D) of mice immunized with HAv, HAv-CT, or
HAv-SF-10 after infection with three lethal doses of IAV/PR8
(H1N1) (50, 250, and 1000  LD50) over a period of 15 days. All
mice that were immunized with HAv(p.o.) died at day 9 after infec-
tion with 50  LD50 IAV/PR8(H1N1) and only 20% of mice immu-
nized with HAv-CT(p.o.) survived. In contrast, all mice
immunized with HAv-SF-10(p.o.) survived following infection with
50  LD50 IAV/PR8(H1N1) (P = 0.004, vs. HAv(p.o.); P = 0.084, vs.
HAv-CT(p.o.)) and also following infection with 250  LD50 and
1000  LD50 IAV/PR8(H1N1). Mice immunized with HAv-SF-10(p.
o.) showed rapid recovery of body weight loss following infection
with 50  LD50 IAV/PR8(H1N1), but recovery delay was detected
after 250 and 1000  LD50 IAV/PR8(H1N1) infection.
4. Discussion
The present study describes several new findings on pulmonary
surfactant mimicking adjuvant SF-10. The findings include i)
Administration of antigen-SF-10(p.o.) enhanced antigen uptakeor without (-) HAv.
Th2 Th17
-4 IL-5 IL-17A IL-22
+  +  +  +
± 0 0 ± 0 0 ± 0 8 ± 8 3 ± 3 36 ± 18 35 ± 7
88 ± 38** 0 ± 0 2143 ± 458* 8 ± 7 60 ± 31** 57 ± 29 562 ± 153**
± 2* 0 ± 0 64 ± 23 1 ± 1 93 ± 70** 59 ± 29 250 ± 87**
± 1* 0 ± 0 70 ± 20 0 ± 0 1469 ± 484** 38 ± 21 1026 ± 364**
± 0** 0 ± 0 1 ± 1* 0 ± 0 5 ± 2** 24 ± 9 44 ± 18**
5 ± 3 0 ± 0 112 ± 43 23 ± 15 9690 ± 1457 219 ± 109 4642 ± 804
nferroni posttest. n = 4–5. *P < 0.05, **P < 0.01, vs HAv-SF-10(p.o.) HAv stimulation(+)
Fig. 4. Optimal time of immunization with HAv-SF-10(p.o.) and immunization efficacy of SF-10 compared with other mucosal adjuvants. Mice were immunized 1–4 times
with HAv-SF-10(p.o.) according to the indicated schedule (A). At 2 weeks after the last immunization, the levels of HAv-specific S-IgA in BALF and HAv-specific IgG in serum
were measured by ELISA (B). Mice were immunized twice at days 0 and 3 with HAv-SF-10(p.o.), or orally immunized with HAv combined with LPS, Pam3CSK4, poly(I:C), CpG,
CT-B or CT. At 2 weeks after the last immunization, the levels of HAv-specific S-IgA in BALF and HAv-specific IgG in serum were measured by ELISA (C). Data represent HAv-
specific S-IgA (circles) in BALF and HAv-specific IgG (squares) in serum of individuals (open) and their means (solid) (n = 5–6). Experiments were independently repeated two
times with 5–6 mice per group and statistical significance was analyzed by using Welch’s t-test. *P < 0.05.
T. Kimoto et al. / Vaccine 37 (2019) 612–622 619into gastrointestinal mucosal APCs. ii) Vaccination with HAv-SF-10
(p.o.) induced systemic and local HAv-specific antibodies in serum
and various mucosal fluids, respectively, higher than those by HAv
(s.c.), HAv-SF-10(i.n.) and HAv(p.o.) vaccinations. HI titers and pro-
tective immunity induced by HAv-SF-10(p.o.) against severe influ-
enza A virus infection were higher than those induced by HAv-CT
(p.o.). iii) Among the mucosal adjuvants tested in this study, which
included adjuvants of microbial origins, SF-10 showed the highest
adjuvanticity in gastrointestinal administration route. iv) Marked
induction of both HAv-specific IgA/S-IgA and IgG antibody-
producing cells in respiratory and gastrointestinal mucosal lymph
nodes of mice immunized with HAv-SF-10(p.o.), compared with
mice immunized with HAv(p.o.). v) Administration of HAv-SF-10
(p.o.) showed unique cytokine induction patterns in the spleen;
highest induction of Th17, high induction of Th1 and moderate
induction of Th2 cytokines.
We reported previously that pulmonary surfactant mimicking
SF-10 adjuvant amplifies antigen uptake into mucosal APCs inthe nasal cavity and induces humoral and cellular immunities
[17]. The natural pulmonary surfactant, which is secreted from
alveolar type II epithelial cells, is absorbed and metabolized rapidly
not only in respiratory mucosa but also gastrointestinal mucosa
cells [18–21,34]. The findings suggest that antigen complexed with
SF-10 is incorporated efficiently into the gastrointestinal mucosa
and APCs and then induces antigen-specific immunities. Indeed,
we found that SF-10 enhanced antigen uptake into intestinal APCs,
such as CD11b+CD103+ DCs and CD11b+CD103- DCs, the major sub-
sets of intestinal DCs for oral vaccination. These DCs primed with
antigen migrate from the intestinal lamina propria to MLN and
present antigen information to T cells [33]. Intestinal CD11b+-
CD103- DCs induce IFN-c-and IL-17-producing effector T cells
[35], and CD11b+CD103+ DCs induce the development of regulatory
T cells and control antigen specific immune tolerance [36]. CD25+-
Foxp3+ regulatory T cells play an important role in intestinal IgA
production [37] and CD11b+CD103+ DCs also induce IgA produc-
tion in the intestine [38]. Since HAv-SF-10(p.o.) vaccination
Fig. 5. Protective immunity induced by HAv-SF-10(p.o.) and survival rates of immunized mice after infection with lethal doses of IAV/PR8/34(H1N1). Mice were immunized
orally with carbo-buffer, HAv, HAv-SF-10 or HAv-CT at days 0 and 3. HI titers were measured at 2 weeks after the last immunization. Data are mean ± SEM of 5–6 mice and
statistical significance was analyzed by using Student’s t-test. *P < 0.05 (A). At 2 weeks after the last immunization, mice were infected with 50  LD50 (50 PFU) of IAV/ PR8/34
(H1N1). Virus titers in BALF of immunized mice were measured at days 4 and 7 after infection. Data are mean ± SEM of 3–10 mice (B). At 2 weeks after the last immunization,
mice were infected with 50  LD50 (50 PFU), 250  LD50 (250 PFU) or 1000  LD50 (1000 PFU) of IAV/ PR8/34(H1N1), and survival rates of each group of mice (C) and body
weight loss (D) were monitored for 15 days after infection (n = 4–5). Data of body weight loss are mean ± SEM of living 4–5 mice in each group during the experimental
period. Significance of survival rates was determined by the Kaplan-Meier method. Experiments were independently repeated three times.
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ciently, SF-10 may stimulate the function of Th17 and regulatory
T cells in the gastrointestinal tract. It has been reported that oral
vaccination induces immune tolerance in general and, if anything,
it is difficult to induce protective immunity efficiently by oral vac-
cination against infectious pathogens compared with other admin-
istration routes of vaccines, such as subcutaneous, intramuscular
and intranasal administrations [39,40]. Efficient induction of pro-
tective immunity by HAv-SF-10(p.o.) vaccination in Fig. 5 may be
derived from effective vaccine delivery across intestinal mucosal
surface barriers and antigen presentation in the gastrointestinal
mucosal APCs, because pulmonary surfactant, the base compound
of SF-10, is absorbed by the intestinal mucosal epithelium and res-
piratory epithelium and metabolized rapidly and physiologically.
To develop an effective influenza vaccination, a simple and easy
inoculation method for mass vaccination is required. Subcutaneous
or intramuscular vaccination requires needles and syringes, and
intranasal vaccination requires spray devices, whereas oral vacci-
nation does not require any special device. In addition, seasonal
human influenza virus infects the respiratory mucosa and highly
pathogenic avian influenza viruses, such as H5N1, infect both res-
piratory and gut mucosa [8]. Thus, it is desirable to induce anti-
influenza virus immunities in both the respiratory and gastroin-
testinal mucosae to prevent such infection. Based on the results
of this study, we propose that oral administration of HAv-SF-10,
which induced higher levels of systemic and mucosal HAv-
specific antibodies compared with other vaccination routes
(Fig. 2), and also induced HAv-specific ASCs in the respiratory
and gastrointestinal mucosal lymphoid tissues (Fig. 3). Notably,
the induced levels of HAv-specific serum IgG and BALF S-IgA and
HI titers by HAv-SF-10(p.o.) were strikingly higher than thoseinduced by HAv-SF-10(i.n.) and HAv(s.c.) (Fig. 2A and B, Table 1).
These results suggest that the adjuvanticity of SF-10 is more effec-
tive on gastrointestinal mucosa than on nasal mucosa. In addition,
the high levels of HAv-specific S-IgA in the gastrointestinal tract
(Fig. 2D and E) and high amounts of HAv-specific ASCs in PP and
MLN (Fig. 3D and E) of mice immunized with HAv-SF-10(p.o.), sug-
gest that oral administration of HAv-SF-10 is potentially suitable
for prevention of influenza virus infection.
Vaccination with HAv-SF-10(p.o) elicited HAv-responsive Th1,
Th2 and Th17 cytokine-producing cells (Table 2). Th1 and Th2 cells
are major subsets of CD4 helper T cells and modulate cellular and
humoral immunity, respectively. In our previous study, immuniza-
tion using HAv-SF-10(i.n.) elicited HAv-responsive Th1 type
cytokine- (IFN-c), and Th2 type cytokine (IL-4)-producing lympho-
cytes and induced antigen specific humoral and cell mediated
immunity [12,17]. In the present study, we found markedly high
HAv responsive IL-17A production levels in mice vaccinated with
HAv-SF-10(p.o.) and HAv-SF-10(i.n.) compared with HAv(p.o.),
HAv(i.n.) and HAv(s.c.). Recently, Th17, a new subset of T helper
cells, was found to produce IL-17A and IL-22 [41] and was related
to the development of antigen-specific IgA ASCs in PP [42]. SF-10
enhanced antigen uptake into intestinal CD11b+CD103- DCs
(Fig. 1), which induced IL-17A producing effector T cells. The find-
ing implies that the induced Th17-mediated immunity is one of the
mechanisms of efficient induction of mucosal S-IgA by HAv-SF-10
(p.o.), although the negative issues of Th17-mediated immune
responses, such as hyperresponsiveness and inflammatory stimu-
lation in the pathogenesis of the respiratory syncytial virus infec-
tion [43] and influenza virus infection [44], have been reported.
Furthermore, immunization with HAv-SF-10(p.o.) induced mild
levels of HAv-responsive IL-4 (Table 2), which induces IgE,
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Indeed, HAv(s.c.) vaccination induced HAv-specific serum IgE
[12] but the levels of IgE induced by HAv-SF-10(p.o.) were below
the detection levels (data not shown).
It has been reported that bacterial- or viral-based mucosal adju-
vants administrated through the intranasal and oral routes induce
both mucosal S-IgA and serum IgG [45]. In the present study, mice
were immunized orally twice with HAv combined with LPS,
Pam3CSK4, poly(IC), CpG, CT-B, CT, or SF-10, in order to compare
the adjuvanticity of SF-10 with these mucosal adjuvants. All adju-
vants other than CT and SF-10 exhibited little or no adjuvanticity.
While SF-10 induced both HAv-specific S-IgA in BALF and IgG in
serum, CT induced HAv-specific IgG in serum only but not HAv-
specific S-IgA in BALF (Fig. 4C). In general, the antigenicity of pro-
teins administered orally degenerates in the low gastric pH envi-
ronment and digestive enzymes in the gastrointestinal tract,
making it difficult to induce effective oral immunization [40]. To
improve antigen stability in gastrointestinal tracts, polymerized
liposomes which are susceptible to be uptaken by Peyer’s patches
and provide superior protection against antigen degeneration have
been reported [46]. Antigen combined with liposome-like adjuvant
SF-10 in carbo-buffer may protect antigen degeneration in the gas-
trointestinal tract and induce effective systemic and local immu-
nity compared with other mucosal adjuvants tested.
For protection against unexpected outbreaks of emerging infec-
tions, it is important to develop effective vaccines that can rapidly
induce robust protective immunity. Immunization with HAv-SF-10
(p.o.) induced potent protective immunity with high HI titers and
neutralization activities against severe IAV infection with a short
period of time in mice (Fig. 5). Although HAv-CT(p.o.) induced
HAv-specific IgG in serum with HI titers > 40 (Fig. 4C and 5A), suf-
ficient levels of HAv-specific S-IgA were lacking in BALF and only
20% of the mice were alive after severe influenza virus challenge.
While the above results highlight the superiority of HAv-SF-10(p.
o.) with regard to the induced systemic and local immunity, com-
pared with the other preparations used in our study, they also indi-
cate that anti-HAv S-IgA levels in the lungs induced by HAv-SF-10
(p.o.) play pivotal roles in protection against IAV infection.
Our study has certain limitations. Oral vaccination shows in
generally two reciprocate aspects, immune tolerance induction
and protective immunity induction, although details of difference
in the mechanisms between them have not been well analyzed.
In the present study, we clarified the protective immunity induced
by HAv-SF-10(p.o.) vaccination, but not yet the immune tolerance
induction. In addition, we suggested that protective immunity
induced by HAv-SF-10(p.o.) is associated with the marked induc-
tion of Th17 cytokines, high induction of Th1 cytokines and mod-
erate induction of Th2 cytokines, although the negative issues of
Th17-mediated immune responses, such as hyperresponsiveness
and inflammatory stimulation in the pathogenesis of viral infection
[43.44], have not been studied yet. To demonstrate the transla-
tional values of our new oral vaccine formulation, further studies
are required. We are planning to clarify these limitations described
above and cell-mediated immunity by HAv-SF-10(p.o.) in mice and
non-human primates.
In conclusion, we have demonstrated in the present study that
SF-10, which mimics human pulmonary surfactant, is a suitable
and effective mucosal adjuvant that can be used for oral route vac-
cination to provide potent and rapid systemic and mucosal
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